



# **Use of Spirometry as an Objective Tool in Diagnosis and Management of Airway Obstruction among Patients Diagnosed and Treated as COPD or Asthma**

*Thesis*

*Submitted for Partial Fulfillment  
of Master Degree in Chest Diseases*

*Presented by*

***Mahmoud Mohamad Yousry Mohamad***

*M.B.B.Ch  
Ain Shams University*

*Supervised by*

**Prof. Mohammad Abdel- Sabour Faramawy**

*Professor of Chest Diseases  
Faculty of Medicine - Ain Shams University*

**Prof. Hesham Atef Abdelhalim**

*Professor of Chest Diseases  
Faculty of Medicine - Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال

سبحانك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

## Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Mohammad Abdel-Sabour Faraway**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Hesham Atef Abdelhalim**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Mahmoud Mohamad Yousry Mohamad**

# List of Contents

Title	Page No.
List of Tables .....	5
List of Figures .....	7
List of Abbreviations.....	9
Introduction.....	- 1 -
Aim of the Work .....	13
Review of Literature	
▪ COPD Review .....	14
▪ Bronchial Asthma Review .....	77
▪ Spirometry .....	128
Patients and Methods .....	151
Results .....	157
Discussion.....	167
Summary .....	178
Conclusion .....	181
Recommendations .....	182
References .....	183
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table (1):</b>	Key Indicators for Considering a Diagnosis of COPD .....	36
<b>Table (2):</b>	Modified Medical Research Council Questionnaire for Assessing the Severity of Breathlessness .....	44
<b>Table (3):</b>	Classification of severity of airflow limitation in COPD (Based on post-bronchodilator FEV <sub>1</sub> ).....	45
<b>Table (4):</b>	COPD and its Differential diagnosis .....	51
<b>Table (5):</b>	Keys of Non- pharmacological treatment of COPD .....	56
<b>Table (6):</b>	Assessment of COPD Exacerbations: Signs of Severity .....	67
<b>Table (7):</b>	Management of Severe but Not Life Threatening Exacerbations* .....	68
<b>Table (8):</b>	Potential Indications for hospitalization assessment .....	69
<b>Table (9):</b>	Therapeutic Components of Hospital Management .....	70
<b>Table (10):</b>	Items to assess at follow-up visit 4-6 weeks after discharge from hospital for exacerbations of COPD .....	75
<b>Table (11):</b>	Factors influencing the development and expression of asthma .....	80
<b>Table (12):</b>	Asthma susceptibility genes:.....	82
<b>Table (13):</b>	Features of airway remodeling: .....	92

## List of Tables cont...

Table No.	Title	Page No.
<b>Table (14):</b>	Asthma phenotypes according to their cytokine profiles divided into Th2-high and Th2-low asthma.....	95
<b>Table (15):</b>	Diagnostic criteria for asthma in adults, adolescents, and children 6–11 years .....	99
<b>Table (16):</b>	Spirometric measures in asthma,COPD and asthma-COPD overlap .....	103
<b>Table (17):</b>	Low, medium and high daily doses of inhaled corticosteroids.....	114
<b>Table (18):</b>	Factors that increase the risk of asthma-related death.....	121
<b>Table (19):</b>	Classification of severity of airflow limitation in COPD (Based on post-bronchodilator FEV1).....	138
<b>Table (20):</b>	Hutchinson terms and recent terms of lung volumes.....	143
<b>Table (21):</b>	Descriptive data of all studied patients:.....	159
<b>Table (22):</b>	Drugs used by patients:.....	160
<b>Table (23):</b>	Assessment of severity of symptoms by mMRC, CAT and ACT score:.....	162
<b>Table (24):</b>	Medications and classification of severity of COPD and bronchial asthma patients:.....	165
<b>Table (25):</b>	Comparison between provisional and final diagnosis after spirometry:.....	166

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Annual decline in airway function in susceptible smokers and effects of smoking cessation. ....	22
<b>Figure (2):</b>	Pathogenesis of COPD. ....	28
<b>Figure (3):</b>	Diagram of the pathogenesis and pathophysiology of COPD. ....	31
<b>Figure (4):</b>	New approach of combined COPD assessment ....	47
<b>Figure (5):</b>	Pharmacological treatment of COPD. ....	58
<b>Figure (6):</b>	Pathogenesis of bronchial asthma (Airway effect) ....	90
<b>Figure (7):</b>	The Asthmatic Airways ....	93
<b>Figure (8):</b>	Immune and inflammatory mechanisms and asthma progression.....	96
<b>Figure (9):</b>	Diagnostic flowchart for clinical practice – initial presentation of bronchial asthma ....	98
<b>Figure (10):</b>	Decision tree for the patient with asthma ....	119
<b>Figure (11):</b>	Self-management of worsening asthma in adults and adolescents with a written asthma action plan.....	125
<b>Figure (12):</b>	Management of asthma exacerbations in primary care (adults, adolescents, children 6–11 years).....	126
<b>Figure (13):</b>	Management of asthma exacerbations in acute care facility, e.g. emergency department ....	127
<b>Figure (14):</b>	Normal spirometry and typical patient with obstructive changes. ....	135

## List of Figures *cont...*

Fig. No.	Title	Page No.
<b>Figure (15):</b>	A gasometer from A Manual of Chemistry, p. 82, by William Thomas Brande, 1819, published by J. Murray, Albermarle Street, London .....	141
<b>Figure (16):</b>	John Hutchinson's spirometer from "On the Capacity of the Lungs and on the Respiratory Functions with a View of Establishing a Precise and Easy Way of Detecting Disease by the Spirometer,".....	142
<b>Figure (17):</b>	Water sealed spirometer. U.S. Patent 26754, by Augustus Eckert, of Dayton, Ohio, filed in 1860. ....	144
<b>Figure (18):</b>	A.P. Barnes' spirometer advertisement from The Herald of Health, Jan. 1875, p. 93. ....	145
<b>Figure (19):</b>	Boudin's spirometer from Rainal Brothers, Leon & Jules, Medical Equipment Catalog, 1905, p. 380. ....	146
<b>Figure (20):</b>	Spirometry, circa 1955 .....	148
<b>Figure (21):</b>	Spirometry 1969 .....	148
<b>Figure (22):</b>	Spirometry, National Cylinder Gas Pulmonary Function Indicator, 1976 .....	149
<b>Figure (23):</b>	Spirometry, Collins S-520, 1984 .....	149
<b>Figure (24):</b>	Spirometers 4000, 1990's .....	150
<b>Figure (25):</b>	A Koko Legend Spirometer .....	150
<b>Figure (26):</b>	(Spirolab III spirometer) (Sprolab III: ID:TUK-MIR009, made by MIR, ROME - ITALY) .....	152
<b>Figure (27):</b>	Comparison between provisional and final diagnosis after spirometry. ....	166



# List of Abbreviations

Abb.	Full term
<i>AATD</i> .....	<i>Alpha-1 antitrypsin defeciency</i>
<i>ABG</i> .....	<i>Arterial blood gases</i>
<i>ACCP</i> .....	<i>American college of chest physicians</i>
<i>ACP</i> .....	<i>American college of physicians</i>
<i>ACT</i> .....	<i>Asthma control test</i>
<i>AECOPD</i> .....	<i>Acute exacerbation of Chronic obstructive pulmonary disease</i>
<i>AERD</i> .....	<i>Aspirin Exacerbated Respiratory Disease</i>
<i>AEs</i> .....	<i>Asthma exacerbations</i>
<i>ATS</i> .....	<i>American respiratory society</i>
<i>BHR</i> .....	<i>Bronchial hyperresponsivness</i>
<i>BS</i> .....	<i>Bronchial thermoplasty</i>
<i>CAT</i> .....	<i>COPD Assessment Test</i>
<i>CCQ</i> .....	<i>COPD Control Questionnaire</i>
<i>CD4</i> .....	<i>Cluster Of Differentiation 4</i>
<i>CD8</i> .....	<i>Cluster Of Differentiation 8</i>
<i>COPD</i> .....	<i>Chronic obstructive pulmonary disease</i>
<i>CXR</i> .....	<i>Chest X-ray</i>
<i>DALYs</i> .....	<i>Disability-Adjusted Life Years</i>
<i>DLco</i> .....	<i>Diffusing capacity of lung for carbon monoxide</i>
<i>ED</i> .....	<i>Emergency department</i>
<i>EIA</i> .....	<i>Exercise induced asthma</i>
<i>ERS</i> .....	<i>European respiratory society</i>
<i>Fev1</i> .....	<i>Forced expiratory volume in 1 second</i>
<i>FLG</i> .....	<i>Filaggrin gene</i>
<i>FRC</i> .....	<i>Functional Residual Capacity</i>
<i>FVC</i> .....	<i>Forced vital capacity</i>
<i>GERD</i> .....	<i>Gastroesophageal reflux</i>
<i>GINA</i> .....	<i>Global Initiative for Athma</i>
<i>GOLD</i> .....	<i>Global Initiative for Chronic Obstructive Lung Disease</i>
<i>ICS</i> .....	<i>Inhaled corticosteroid</i>

## List of Abbreviations *cont...*

Abb.	Full term
<i>IFN</i> .....	<i>Interferon</i>
<i>IgE</i> .....	<i>Immunoglobulin E</i>
<i>IL</i> .....	<i>Interlukin</i>
<i>ISAAC</i> .....	<i>International study of asthma and allergies in childhood</i>
<i>LABA</i> .....	<i>Long acting Beta 2 agonist</i>
<i>LAMA</i> .....	<i>Long acting muscarinic antagonist</i>
<i>LTRA</i> .....	<i>Leukotriens receptor antagonist</i>
<i>MMP12</i> .....	<i>Matrix metalloproteinase 12</i>
<i>mMRC</i> .....	<i>Modified British Medical Research Council</i>
<i>NIV</i> .....	<i>Non invasive ventilation</i>
<i>Nrf2</i> .....	<i>Nuclear factor erythroid 2-related factor 2</i>
<i>OCS</i> .....	<i>Oral corticosteroids</i>
<i>OSHA</i> .....	<i>Occupational safety and health administration</i>
<i>PEF</i> .....	<i>Peak expiratory flow</i>
<i>PFT</i> .....	<i>Pulmonary function test</i>
<i>RV</i> .....	<i>Rhinovirus</i>
<i>SABA</i> .....	<i>Short acting Beta2 agonist</i>
<i>SAMA</i> .....	<i>Short acting muscarinic antagonist</i>
<i>SARP</i> .....	<i>Severe Asthma Research Program</i>
<i>SPT</i> .....	<i>Skin prick test</i>
<i>TLC</i> .....	<i>Total Lung Capacity</i>
<i>TNF</i> .....	<i>Tumor necrosis factor</i>

## INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles and gases (*GOLD, 2017*).

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It's defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation (*GINA, 2017*).

Spirometry is essential for the assessment of patients with suspected chronic disease of the airways. It must be performed at either the initial or subsequent visit if possible before and after a trial of treatment. Early confirmation or exclusion of the diagnosis of chronic airflow limitation may avoid needless trial of therapy, or delays in initiating other investigations (*GINA, 2017*).

The diagnosis of COPD should be considered in any patient who has the following: symptoms of cough, sputum production, or dyspnea, or history of exposure to risk factors of the disease (exposure to cigarettes, and/or occupational or

environmental pollutants).The diagnosis requires spirometry; a post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC)  $\leq 0.7$  confirms the presence of airflow limitation that is not reversible (*Celi et al., 2004*).

Screening spirometry influences physicians' diagnosis of airflow obstruction and management plans especially in patients with moderate to severe obstruction (*Robert, 2005*). Misdiagnosis of COPD or Asthma leads to inadequate management of patients and to escalating healthcare costs. An early and accurate diagnosis can help to ensure optimal and cost-effective management of patient care (*Kuebler et al., 2008*).

Objective confirmation of airway obstruction is essential in preventing misdiagnosis in frequent severe exacerbators of clinically diagnosed asthma and COPD. Spirometry utilization is strongly associated with a reduced risk of misdiagnosis (*Jain et al., 2015*).

## **AIM OF THE WORK**

To assess use of spirometry as an objective tool in diagnosis and management of patients treated of obstructive lung diseases (Asthma and COPD).

## Chapter 1:

# COPD REVIEW

### Definitions:

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease that is characterised by persistent symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases (*GOLD, 2018*).

Chronic obstructive pulmonary disease (COPD) refers to a group of diseases that cause airflow blockage and breathing-related problems. It include chronic bronchitis, emphysema, and in some cases asthma (*Centers for Disease Control and Prevention, 2015*).

COPD is characterized by airflow obstruction that is not fully reversible. The airflow obstruction does not change markedly over several months and is usually progressive in the long term. COPD is predominantly caused by smoking. Other factors, particularly occupational exposures, may also contribute to the development of COPD. Exacerbations often occur, where there is a rapid and sustained worsening of symptoms beyond normal day-to-day variations (*Nice, 2010*).

Asthma and chronic obstructive pulmonary disease (COPD) are traditionally recognized as distinct diseases. However, the difference between the two is not always clear. Patients with severe asthma may present with fixed airway obstruction, and patients with COPD may have hyper-responsiveness and eosinophilia. Recognizing and understanding these overlapping features, may offer new insight into the mechanisms and treatment of chronic airway inflammatory diseases (*Kim and Rhee, 2010*).

### **Burden of (COPD)**

**Epidemiology:** COPD is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing. COPD prevalence, morbidity, and mortality vary across countries and across different groups within countries. COPD is the result of cumulative exposures over decades. Often, the prevalence of COPD is directly related to the prevalence of tobacco smoking, although in many countries, outdoor, occupational and indoor air pollution, are major COPD risk factors. The prevalence and burden of COPD are projected to increase in the next decades due to frequent exposure to risk factors and the aging of the world's population (*GOLD, 2018*).

### **Prevalence:**

Approximately 65 million people have moderate-to-severe COPD (*WHO, 2015*).